FS 102

Drug Profile

FS 102

Alternative Names: BMS-986186; BMS-986186-01; FS102

Latest Information Update: 28 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator f-star
  • Developer Bristol-Myers Squibb
  • Class Antineoplastics; Bispecific antibodies; Drug conjugates; Immunoglobulin Fc fragments; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Breast cancer; Gastric cancer
  • No development reported Solid tumours

Most Recent Events

  • 28 Dec 2017 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in Canada (IV, Infusion)
  • 28 Dec 2017 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in USA (IV, Infusion)
  • 09 Oct 2017 Heidelberg Pharma is now called Heidelberg Pharma Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top